Biocryst Pharmaceuticals (BCRX) Change in Account Payables (2014 - 2026)

Biocryst Pharmaceuticals has reported Change in Account Payables for 13 years, with the latest figure at -$60.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables fell 85.29% year-over-year to -$60.4 million; the trailing twelve-month figure through Mar 2026 stood at $30.0 million (up 12.15% YoY), and the FY2025 full-year result was $57.8 million, up 291.19% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$60.4 million, down from $35.4 million in the prior quarter.
• The five-year high for Change in Account Payables was $49.2 million in Q4 2023, with the low at -$60.4 million in Q1 2026.
• Historically, Change in Account Payables has averaged $138470.6 across 5 years, with a median of $5.3 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Account Payables tumbled 237.47% — and 2024, when it surged 11022.87%.
• Biocryst Pharmaceuticals' Change in Account Payables stood at $5.3 million in 2022, then jumped by 832.17% to $49.2 million in 2023, then slumped by 58.54% to $20.4 million in 2024, then jumped by 73.33% to $35.4 million in 2025, then slumped by 270.8% to -$60.4 million in 2026.
• The last three Change in Account Payables figures came in at -$60.4 million (Q1 2026), $35.4 million (Q4 2025), and $24.6 million (Q3 2025), per Business Quant data.